EUVIMEDEUVIMED entdecken
Vergleichsstudie

Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study

Fabrizia Mealli, Alessandra Mattei, Alice Mariottini iD, Luca Massacesi

Multiple Sclerosis Journal · 2024

DOI: 10.1177/13524585241238136 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Fabrizia Mealli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics Informatics and Applications 'Giuseppe Parenti', University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Administration, Intravenous, Natalizumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of efficacy of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing the REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions of the effect size of NTZ-IV versus placebo observed in the AFFIRM study. Ninety-nine RRMS were included. NTZ-SC resulted not inferior to NTZ-IV on CUAL for all margins at 2.5% significance level, and, in worst-case scenario, its effect over NTZ-IV did not exceed 3.5% (or 2.8%) of the effect of NTZ-IV versus placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, IntravenousNatalizumabAdultFemaleHumansMaleMiddle AgedImmunologic FactorsInjections, SubcutaneousMagnetic Resonance ImagingMultiple Sclerosis, Relapsing-RemittingDrug Administration Schedule

Stichwörter der Autor:innen

Natalizumabdisease-modifying therapiesmultiple sclerosisnon-inferiority studysecond-line treatmentsubcutaneous

Substanzen

Immunologic FactorsNatalizumab

Autor:innen und Institutionen

  • Department of Statistics Informatics and Applications 'Giuseppe Parenti', University of Florence, Florence, Italy.
  • Florence Centre for Data Science, Florence, Italy.
  • Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
  • Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.

ORCID-Profile: Alice Mariottini

Zitieren

APA

Mealli, F., Mattei, A., Mariottini, A., & Massacesi, L. (2024). Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241238136

Vancouver

Mealli F, Mattei A, Mariottini A, Massacesi L. Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241238136

BibTeX
@article{Mealli2024,
  author = {Mealli, Fabrizia and Mattei, Alessandra and Mariottini, Alice and Massacesi, Luca},
  title = {Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  doi = {10.1177/13524585241238136}
}
Kostenlos starten →